The explosive growth in demand for GLP-1 receptor agonists — particularly semaglutide and tirzepatide — for weight management and diabetes treatment has created both significant opportunity and significant regulatory complexity for compounding pharmacies across the United States.
This guide breaks down what compounding pharmacies need to understand about GLP-1 APIs: what they are, why they’ve become so important, the regulatory environment that governs compounding with them, and what to look for in an API supplier if you’re operating in this space.
What Are GLP-1 Receptor Agonists?
Glucagon-Like Peptide-1 (GLP-1) receptor agonists are a class of medications that mimic the action of the body’s naturally occurring GLP-1 hormone. They work primarily by stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon release, slowing gastric emptying, and reducing appetite — resulting in both blood sugar control (for Type 2 diabetes) and significant weight reduction (for obesity and weight management).
The most prominent GLP-1 agents relevant to compounding pharmacy include:
- Semaglutide (brand names: Ozempic® for diabetes, Wegovy® for weight management) — weekly subcutaneous injection or oral tablet (Rybelsus®)
- Tirzepatide (brand names: Mounjaro® for diabetes, Zepbound® for weight management) — a dual GLP-1/GIP receptor agonist, weekly subcutaneous injection
Why Compounding Pharmacies Have Been Involved
Beginning in 2022 and continuing through 2024, both semaglutide and tirzepatide experienced severe supply shortages as demand dramatically outpaced commercial manufacturing capacity. The FDA maintains a Drug Shortage list, and when an FDA-approved drug appears on this list, it creates a legal pathway for compounding pharmacies and outsourcing facilities (503Bs) to compound copies of the drug to address the shortage — even if the drug is not on the FDA’s approved compounding drug list.
This is the legal basis under which many compounding pharmacies began preparing semaglutide and tirzepatide formulations. The law permitting this is Section 503A of the Federal Food, Drug, and Cosmetic Act (for traditional compounding pharmacies) and Section 503B (for outsourcing facilities).
The Critical Regulatory Distinction: Base vs. Salt Forms
One of the most consequential regulatory issues in GLP-1 compounding involves the form of semaglutide being used. The FDA-approved commercial products use semaglutide base (the free-form peptide). Many suppliers have marketed semaglutide as acetate or sodium salt forms.
The FDA issued guidance stating that semaglutide acetate and similar salts are not the same active moiety as the FDA-approved drug, and therefore compounding using these salt forms may not qualify for the shortage exemption. This distinction has significant compliance implications. Always verify which specific form of a GLP-1 API you are sourcing and whether it matches the form referenced in any FDA guidance documents.
Shortage Status and Its Regulatory Implications
The FDA removed semaglutide from its official shortage list in early 2025 after commercial manufacturers resolved supply constraints. When a drug is removed from the shortage list, the legal pathway for compounding under the shortage exemption closes — and 503A pharmacies must cease compounding that drug except for specific patient need scenarios (documented allergy to a commercial product excipient, etc.).
The regulatory landscape for GLP-1 compounding continues to evolve rapidly. Pharmacies operating in this space must monitor FDA communications and state board guidance closely.
API Quality Requirements for GLP-1 Peptide APIs
GLP-1 receptor agonists are peptide-based APIs — complex molecules that require specialized manufacturing and analytical testing compared to small-molecule APIs. Key quality parameters include:
- Peptide purity — typically ≥98% by HPLC for pharmaceutical-grade material
- Peptide content — actual peptide mass relative to total material weight (accounting for counter-ions, water content)
- Related substances and impurity profiles — identification of all related peptide impurities above specified thresholds
- Endotoxin/pyrogen testing — critical for injectable preparations
- Microbial contamination
- Molecular mass confirmation — MS verification of the correct peptide sequence
- Storage conditions — most peptide APIs require refrigeration (2-8°C) with protection from light and moisture
What to Look for in a GLP-1 API Supplier
Given the regulatory sensitivity around GLP-1 compounding, your API supplier selection is especially critical in this space. Look for suppliers who can provide:
- Unambiguous specification of the exact chemical form (base, not salt, unless specifically intended)
- HPLC purity certificate ≥98% from an accredited laboratory
- Mass spectrometry confirmation of molecular identity
- Endotoxin test results (for facilities performing sterile compounding)
- Full impurity profile documentation
- Cold chain shipping with temperature monitoring
- Clear regulatory guidance about current FDA shortage status
MedConnectRx maintains current sourcing relationships for pharmaceutical-grade peptide APIs and monitors the regulatory landscape on behalf of our pharmacy partners. Contact our team to discuss your specific GLP-1 sourcing needs and current availability.